Most Popular - Medivation (MDVN) has made a rapid come-back since investors exited en masse in mid-June as the company’s closest development-stage competitor was bought by J&J (JNJ). … Continue Reading
Read nowLong Ideas - On Monday after the close, Achillion Pharmaceuticals (ACHN) revealed that the FDA has placed a partial clinical hold on the development of lead candidate sovaprevir … Continue Reading
Read nowLong Ideas - ICPT has a big problem, and could be headed back to its post-IPO prices, 50% lower than where they trade today. The company piqued our … Continue Reading
Read nowLong Ideas - Since our last report on Achillion Pharmaceuticals (ACHN) in November, shares have turned up a muted performance, losing around 7%. Through February, shares rose steadily, … Continue Reading
Read nowLong Ideas - As investors packed up in search of more exciting prospects, shares of OraSure Technologies (OSUR) have been slashed in half since their highs in mid-2012, … Continue Reading
Read nowLong Ideas - PropThink’s first story of the week turned into a whopping 24% gainer by Friday’s close. We iterated our enthusiasm for Pharmacyclics (PCYC) on Monday, following … Continue Reading
Read nowLong Ideas - Gilead Sciences announced Tuesday morning that its Hepatitis C (HCV) candidate sofosbuvir (formerly GS-7977) in combination with ribavirin attained a 78% Sustained Virologic Response (SVR) … Continue Reading
Read now